Association Institut De Myologie
- Address
- lock Available on a paid plan
Congenital and Hereditary Diseases in Muscle Disorders
At the Association Institut De Myologie in Paris, research in this area focuses on Duchenne Muscular Dystrophy, a serious inherited condition that weakens muscles over time. The trials are designed to explore new ways to slow disease progression and support better long-term outcomes for affected patients.
- Testing a new gene therapy approach for boys who can still walk
- Assessing whether treatment can improve clinical effectiveness and maintain muscle function
- Evaluating the safety and tolerability of emerging therapies over time
This work combines genetic medicine and neuromuscular research to address the underlying cause of the disease while also monitoring how well patients respond to treatment.
Musculoskeletal Diseases and Therapy Development
Clinical research at this site also examines treatment options for Duchenne muscular dystrophy in patients with more advanced mobility loss. The main goal is to determine whether a new therapy can help reduce muscle decline and preserve remaining physical function.
- Evaluating a treatment intended to slow muscle deterioration
- Measuring treatment effectiveness in non-ambulant patients
- Studying the overall safety and tolerability of the therapy
These studies reflect an ongoing effort in musculoskeletal medicine to improve care for people living with progressive inherited muscle disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 6 therapeutic areas and 15 of 25 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1Vertex Pharmaceuticals Inc.2active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Vertex Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Association Institut De Myologie
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Dose-Escalation and Comparative Study of Eteplirsen in Duchenne Muscular Dystrophy Patients with Exon 51 Skipping Mutations | Sarepta Therapeutics Inc. | Phase III | Not Recruiting | Dec 2021 | — |
IMP list
lock Showing 1 of 25 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sirolimus | 2 | Unknown | 2021-03-01 | 2021-03-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.